Rafael Morales‐Barrera

5.0k total citations
111 papers, 1.4k citations indexed

About

Rafael Morales‐Barrera is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rafael Morales‐Barrera has authored 111 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Surgery, 45 papers in Oncology and 42 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rafael Morales‐Barrera's work include Bladder and Urothelial Cancer Treatments (51 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Urinary and Genital Oncology Studies (24 papers). Rafael Morales‐Barrera is often cited by papers focused on Bladder and Urothelial Cancer Treatments (51 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Urinary and Genital Oncology Studies (24 papers). Rafael Morales‐Barrera collaborates with scholars based in Spain, United States and United Kingdom. Rafael Morales‐Barrera's co-authors include Manjit S. Bains, Joan Carles, Weiji Shi, Cristina Suárez, David Amar, Howard T. Thaler, Dorothy A. White, Claudia Valverde, Yohann Loriot and Nicolas Penel and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Surgery.

In The Last Decade

Rafael Morales‐Barrera

98 papers receiving 1.3k citations

Peers

Rafael Morales‐Barrera
Carolyn D. Seib United States
Christopher W. Seder United States
Dorin Colibaseanu United States
Masakazu Ikenaga Japan
Insoo Suh United States
Cecilia G. Ethun United States
Hae Myung Jeon South Korea
Lloyd A. Mack Canada
Carrie C. Lubitz United States
Gabriella Farina Italy
Carolyn D. Seib United States
Rafael Morales‐Barrera
Citations per year, relative to Rafael Morales‐Barrera Rafael Morales‐Barrera (= 1×) peers Carolyn D. Seib

Countries citing papers authored by Rafael Morales‐Barrera

Since Specialization
Citations

This map shows the geographic impact of Rafael Morales‐Barrera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafael Morales‐Barrera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafael Morales‐Barrera more than expected).

Fields of papers citing papers by Rafael Morales‐Barrera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafael Morales‐Barrera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafael Morales‐Barrera. The network helps show where Rafael Morales‐Barrera may publish in the future.

Co-authorship network of co-authors of Rafael Morales‐Barrera

This figure shows the co-authorship network connecting the top 25 collaborators of Rafael Morales‐Barrera. A scholar is included among the top collaborators of Rafael Morales‐Barrera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafael Morales‐Barrera. Rafael Morales‐Barrera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hansen, Aaron R., Alison Yan Zhang, Valentina Boni, et al.. (2025). A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).. Journal of Clinical Oncology. 43(5_suppl).
3.
Sweis, Randy F., Pablo Gajate, Rafael Morales‐Barrera, et al.. (2024). Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer. JAMA Oncology. 10(11). 1565–1565. 6 indexed citations
4.
Powles, T.B., Christof Vulsteke, M. Gross Goupil, et al.. (2024). LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis. Annals of Oncology. 35. S1505–S1507. 4 indexed citations
5.
Powles, Thomas, Tibor Csőszi, Yohann Loriot, et al.. (2024). Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study. Clinical Genitourinary Cancer. 23(1). 102261–102261.
6.
Bakaloudi, Dimitra Rafailia, Dimitrios Makrakis, Nishita Tripathi, et al.. (2023). Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology. 41(16_suppl). 4574–4574.
7.
Grivas, Petros, Srikala S. Sridhar, Begoña P. Valderrama, et al.. (2023). 2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC). Annals of Oncology. 34. S1209–S1210. 2 indexed citations
8.
Morales‐Barrera, Rafael, Guillermo Villacampa, Teresa Bonfill, et al.. (2023). Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment. Clinical & Translational Oncology. 25(12). 3556–3564. 1 indexed citations
9.
Suárez, Cristina, Rafael Morales‐Barrera, Joaquı́n Mateo, et al.. (2022). Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease. Frontiers in Oncology. 12. 970199–970199. 12 indexed citations
10.
Suárez, Cristina, et al.. (2021). Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. Current Opinion in Urology. 31(3). 242–248. 3 indexed citations
11.
Carles, Joan, Teresa Alonso, B. Mellado González, et al.. (2020). 639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide. Annals of Oncology. 31. S525–S526. 1 indexed citations
12.
Alva, Ajjai, Tibor Csőszi, Mustafa Özgüroğlu, et al.. (2020). LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Annals of Oncology. 31. S1155–S1155. 47 indexed citations
13.
Alba, Aranzazu González del, Guillermo de Velasco, Núria Laínez, et al.. (2018). SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). Clinical & Translational Oncology. 21(1). 64–74. 15 indexed citations
14.
Carles, Joan, Enrique Gallardo, Montserrat Domènech, et al.. (2018). Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 103(2). 344–352. 5 indexed citations
15.
16.
Moreno, Víctor, David Olmos, Carlos Gomez‐Roca, et al.. (2014). Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research. 20(22). 5663–5671. 14 indexed citations
17.
Carretón, Elena, et al.. (2013). SDS-PAGE analysis of urinary proteins in dogs with heartworm disease. Majallah-i taḥqīqāt-i dāmpizishkī-i īrān. 14(3). 245–249. 1 indexed citations
18.
Deutsch, Gary B., et al.. (2010). Bleeding Risk Secondary to DVT Prophylaxis in Patients With Lower GI Bleeding. CHEST Journal. 138(4). 236A–236A.
19.
Gupta, Rajeev, et al.. (2009). THE EFFECT OF LOW BODY MASS INDEX ON OUTCOME IN CRITICALLY ILL SURGICAL PATIENTS. CHEST Journal. 136(4). 27S–27S. 2 indexed citations
20.
Groeger, Jeffrey S., et al.. (2000). The effect of varying inspiratory flow waveforms on pulmonary mechanics in critically ill patients. Journal of Critical Care. 15(4). 133–136. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carolyn D. Seib Breakdown of academic impact, for papers by Christopher W. Seder Breakdown of academic impact, for papers by Dorin Colibaseanu Breakdown of academic impact, for papers by Masakazu Ikenaga Breakdown of academic impact, for papers by Insoo Suh Breakdown of academic impact, for papers by Cecilia G. Ethun Breakdown of academic impact, for papers by Hae Myung Jeon Breakdown of academic impact, for papers by Lloyd A. Mack Breakdown of academic impact, for papers by Carrie C. Lubitz Breakdown of academic impact, for papers by Gabriella Farina
Rankless by CCL
2026